Can You Prescribe Spiriva (Tiotropium) for Her?
Yes, you can prescribe Spiriva (tiotropium) for her if she is ≥12 years old with moderate-to-severe asthma that remains uncontrolled despite treatment with inhaled corticosteroids (ICS) ± long-acting beta-agonists (LABAs). 1
FDA-Approved Indications for Asthma
Spiriva (tiotropium) was approved in the United States in 2015 for asthmatic patients aged 12 years or older as once-daily maintenance treatment 1. The FDA label specifies this is for maintenance treatment of asthma, not for acute rescue 2.
Key Dosing Differences by Indication:
- For asthma: 2.5 μg once daily (via Respimat inhaler) 3
- For COPD: 5 μg once daily or 18 μg via HandiHaler 3
Critical point: The asthma dose (2.5 μg) is actually lower than the COPD dose and demonstrated superior pulmonary function outcomes compared to the 5 μg dose in asthma trials 3.
When to Prescribe: Treatment Algorithm
Step 1: Verify Age and Diagnosis
- Patient must be ≥12 years old 1
- Confirmed asthma diagnosis (not COPD or asthma-COPD overlap)
Step 2: Assess Current Treatment Level
Tiotropium is appropriate when:
- Patient is on high-dose ICS (≥800 μg budesonide/day equivalent) + LABA with inadequate control 1
- OR patient is on medium-dose ICS with persistent symptoms 1
- This corresponds to GINA Steps 4-5 4, 5
Step 3: Document Inadequate Control
Patient should have:
- One or more severe exacerbations in the previous year 4
- OR persistent symptoms despite optimized ICS/LABA therapy 1
Step 4: Rule Out Contraindications
Do NOT prescribe if she has 2:
- Allergy to tiotropium, ipratropium, or atropine
- Severe milk protein allergy (capsules contain lactose)
Use with extreme caution if she has 2:
- Narrow-angle glaucoma (can precipitate acute attacks)
- Urinary retention or bladder obstruction
- Severe renal impairment (drug is renally cleared)
Expected Benefits
Based on guideline-level evidence 1:
- Improved lung function: Increases FEV1 non-inferiorly to salmeterol and superiorly to placebo
- Reduced exacerbations: Particularly in severe asthma
- Bronchodilation for 24 hours: Allows once-daily dosing
- Works independently of eosinophilic phenotype: Effective in both high and low Type 2 inflammation 1
Critical Safety Warnings from FDA Label
Immediate Medical Attention Required If She Develops 2:
Acute narrow-angle glaucoma symptoms:
- Eye pain, blurred vision, visual halos with red eyes
- Action: Stop tiotropium immediately, refer to ophthalmology
Urinary retention symptoms:
- Difficulty passing urine, painful urination
- Action: Stop tiotropium immediately, evaluate for obstruction
Paradoxical bronchospasm:
- Immediate worsening of breathing after inhalation
- Action: Discontinue permanently, use rescue inhaler
Common Pitfalls to Avoid:
- Do NOT use as rescue medication - this is maintenance therapy only 2
- Do NOT combine with other anticholinergics (e.g., ipratropium) - increases adverse effects 2
- Ensure proper inhaler technique - capsules must be inhaled via HandiHaler device, never swallowed 2
- Warn about dizziness/blurred vision - may impair driving 2
Special Populations
Black Patients:
One study showed tiotropium + ICS was non-inferior to LABA + ICS in Black patients with asthma, suggesting it may be particularly appropriate in this population 1.
Adolescents (12-17 years):
Safety and tolerability in the 48-week adolescent study was consistent with adult data 1.
Refractory Asthma:
For the 10-15% of patients with persistent airflow limitation despite maximal therapy, tiotropium may provide additional benefit, though some limitation may be due to irreversible small-airway remodeling 1.
Practical Prescribing
Write the prescription as:
- Tiotropium 2.5 μg (Spiriva Respimat)
- Two puffs once daily
- For asthma maintenance (not COPD dose)
Patient counseling must include 2:
- Take at the same time each day
- Not for acute symptoms - continue rescue inhaler
- Store capsules in sealed blisters until use
- Report eye pain, vision changes, or urinary symptoms immediately
- May cause dry mouth (most common side effect)